BioSpace News Archive

Alpheus™ Medical, Inc, a privately held company developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers, today announced the formation of their Scientific Advisory Board (SAB) with the appointment of the world’s leading experts in the fields of neuro-oncology, neurosurgery, chemistry, and molecular biology.

Johnson & Johnson Vision Care, Inc.,* a global leader in eye health and part of the Johnson & Johnson Medical Device Companies,† today announced that the U.S. Food and Drug Administration (FDA) has approved ACUVUE® Theravision™ with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen).

Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, announced its participation in two investor conferences in March.

Yield10 Bioscience, Inc. today announced that the Company will report its fourth quarter and full year 2021 financial results and provide a corporate update on Wednesday, March 9, 2022.

Creative Medical Technology Holdings, Inc. announced the appointment of Sahil Nock as the Company’s Chief Commercial Officer, effective February 28, 2022.

Hillstream BioPharma, Inc. (NASDAQ: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, provided a webcast replay of the Company’s R&D Day held on February 24, 2022.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in two virtual investor conferences in March 2022.

Capricor Therapeutics announced the expansion of its Senior Leadership team with the appointment of Daniel Paulson, M.D. as Vice President of Clinical Development.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed initial bench top, long-term stimulation testing on a novel design of its thin film electrode technology.

Hallura Ltd., an Israeli aesthetic medical company developing next generation Hyaluronic Acid (HA) Dermal Fillers with its proprietary BiOLinkMatrix platform, announced today successful topline results from its multi-site European clinical trial in three indications for lips enhancement, nasolabial folds correction and cheeks enhancement.